Drug Profile
Reteplase
Alternative Names: BM 06022; r PA; Rapilysin; RetavaseLatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Roche
- Developer AbbVie; Chiesi USA; EKR Therapeutics
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myocardial infarction
- Discontinued Embolism
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
- 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici